# Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy

> **NCT04359784** · PHASE2 · COMPLETED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 27 (actual)

## Conditions studied

- B-Cell Non-Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** Anakinra
- **PROCEDURE:** X-Ray Imaging
- **PROCEDURE:** Positron Emission Tomography
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Bone Marrow Biopsy
- **PROCEDURE:** Lumbar Puncture
- **PROCEDURE:** Biospecimen Collection

## Key facts

- **NCT ID:** NCT04359784
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-27
- **Primary completion:** 2024-10-01
- **Final completion:** 2024-12-23
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2025-10-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04359784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04359784, "Anakinra for the Prevention of Cytokine Release Syndrome and Neurotoxicity in Patients With B-Cell Non-Hodgkin Lymphoma Receiving CD19-Targeted CAR-T Cell Therapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04359784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*